Advertisement

Topics

CytomX advances CD71-targeting probody drug conjugate into GLP toxicology studies

05:44 EDT 30 Jun 2017 | Pharmaceutical Business Review

CytomX Therapeutics has advanced CX-2029, a probody drug conjugate (PDC) targeting CD71 and being developed in collaboration with AbbVie, into GLP toxicology studies, an important step on the path to filing an Investigational New Drug (IND) application next year.

Original Article: CytomX advances CD71-targeting probody drug conjugate into GLP toxicology studies

NEXT ARTICLE

More From BioPortfolio on "CytomX advances CD71-targeting probody drug conjugate into GLP toxicology studies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...